The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozkiewicz, Dariusz, Hermanowicz, Justyna Magdalena, Tankiewicz-Kwedlo, Anna, Sieklucka, Beata, Pawlak, Krystyna, Czarnomysy, Robert, Bielawski, Krzysztof, Surazynski, Arkadiusz, Kalafut, Joanna, Przybyszewska, Alicja, Koda, Mariusz, Jakubowska, Katarzyna, Rivero-Muller, Adolfo, Pawlak, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717683/
https://www.ncbi.nlm.nih.gov/pubmed/32912025
http://dx.doi.org/10.1080/14756366.2020.1818738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717683/
https://www.ncbi.nlm.nih.gov/pubmed/32912025
http://dx.doi.org/10.1080/14756366.2020.1818738

Ejemplares similares